SIPAI HEALTH(00314.HK) closed 13.9% lower, the Hang Seng Pharmaceuticals & Biotechnology Sector saw divergent trends
New time space news-By the close of trading on Apr 17, 2026, SIPAI HEALTH(00314.HK) saw a loss of 13.9% in its share price, closing at HKD 1.61. During the session, it reached an intraday high of HKD 1.87 and touched an intraday low of HKD 1.6. The full-day turnover stood at HKD 5.09 million, with the latest market capitalization at HKD 1.19 billion.
On the sector front, the Hang Seng Pharmaceuticals & Biotechnology Sector, to which SIPAI HEALTH belongs, showed an overall divergence trend, with 49 stocks advancing and 94 stocks declining.Among the gainers, NT PHARMA closed higher by 21.43%, HANXBIO-B closed higher by 8.85%, TYCOON GROUP closed higher by 8%, BRII-B closed higher by 6.38%, HIGHTIDE-B closed higher by 5.21%.Among the decliners, SIPAI HEALTH closed lower by 13.9%, LEADS BIOLABS-B closed lower by 8.52%, GENFLEET-B closed lower by 7.63%, 160 HEALTH closed lower by 7.62%, AIM VACCINE closed lower by 7.29%.
NewTimeSpace Disclaimer:All content herein is the original work of NewTimeSpace. Any reproduction, reprinting, or use of this content in any other manner must clearly indicate the source as "NewTimeSpace". NewTimeSpace and its authorized third-party information providers strive to ensure the accuracy and reliability of the data, but do not guarantee the absolute correctness thereof. This content is for reference only and does not constitute any investment advice. All transaction risks shall be borne by the user.
- SIPAI HEALTH (00314.HK): Completion of acquisition of 100% equity interest in Jianyi Information Technology
- SIPAI HEALTH(00314.HK): 2026 Interim Report - Profit Attributable to Shareholders stood at CNY 43.29 million, turned profitable from a loss YoY
- HK Stock Connect Insight | JS GLOBAL LIFESTYLE (01691.HK) Rebounds Over 13% Since Removal; Controlling Shareholder Plans to Pledge 52.87% Stake on October 16
- YZYBIO-B (02496.HK): Proposes Issuing 35.59 Million Domestic Shares to Three Directors at RMB 2.43 Each, Raising about RMB 83 Million; Whitewash Waiver Sought and Trading to Resume
- GLOBAL BIO-CHEM (00809.HK): Boiler Renovation Project Completed and Commissioned; Coenzyme Q10 Project Civil Works Started at Dehui Base